​

BlossomHill Therapeutics Stock (NASDAQ:BLSM)

FinancialsChart

Previous Close

$16.88

52W Range

$15.25 - $27.99

50D Avg

$19.59

200D Avg

$19.59

Market Cap

$508.34M

Avg Vol (3M)

$258.35K

Beta

-

Div Yield

-

BLSM Company Profile

Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

69

IPO Date

Aug 07, 2026

Website

BLSM Performance

BLSM Financial Summary

Dec 25Dec 24
Revenue--
Operating Income$-64.02M$-36.40M
Net Income$-60.55M$-30.70M
EBITDA$-63.58M$-36.05M
Basic EPS$-2.08$-1.06
Diluted EPS$-2.08$-1.06

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
ALLRAllarity Therapeutics, Inc.
AVBPArriVent BioPharma, Inc.
GLUEMonte Rosa Therapeutics, Inc.
RLAYRelay Therapeutics, Inc.
NRIXNurix Therapeutics, Inc.
AGIOAgios Pharmaceuticals, Inc.
PRLDPrelude Therapeutics Incorporated
FTHFaeth Therapeutics, Inc.
FHTXFoghorn Therapeutics Inc.
ACTUActuate Therapeutics Inc